Stock listing
NASDAQ:SBFM Sunshine Biopharma Inc. Stock
Home listing (NASDAQ) of Sunshine Biopharma Inc.
Follow Sunshine Biopharma Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:SBFM
$2.23 USD -0.18 (-7.5%)
Close on Nov 20, 2026
- Day range
- $2.23 – $2.35 USDNov 20, 2026
- Volume
- 22,863 sharesNov 20, 2026
- Market cap
- $1.84M USDAt the close on Nov 20, 2026 · price × 823,772 shares outstanding
- 52-week range
- $2.23 – $464.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $248,758 USDMedian day 2,548 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SBFM · Home | $2.23 USD | -0.18 (-7.5%) | 22,863 | $2.32 | $2.35 | $2.23 | $2.41 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SBFM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.23 | -0.18 | -7.5% | $2.32 | $2.35 | $2.23 | 22,863 | |
| $2.41 | -0.13 | -5.1% | $2.52 | $2.52 | $2.41 | 16,230 | |
| $2.54 | -0.06 | -2.3% | $2.59 | $2.59 | $2.51 | 25,880 | |
| $2.60 | -0.10 | -3.7% | $2.61 | $2.68 | $2.55 | 36,863 | |
| $2.70 | -0.14 | -4.9% | $2.72 | $2.775 | $2.70 | 27,454 | |
| $2.84 | +0.09 | +3.3% | $2.70 | $2.95 | $2.69 | 48,819 | |
| $2.75 | -0.10 | -3.5% | $2.78 | $2.82 | $2.709 | 45,498 | |
| $2.85 | +0.10 | +3.6% | $2.75 | $2.85 | $2.69 | 40,092 | |
| $2.75 | +0.04 | +1.5% | $2.76 | $2.82 | $2.70 | 17,094 | |
| $2.71 | -0.08 | -2.9% | $2.73 | $2.85 | $2.68 | 35,947 | |
| $2.79 | +0.14 | +5.3% | $2.69 | $2.91 | $2.53 | 70,609 | |
| $2.65 | -0.09 | -3.3% | $2.77 | $2.82 | $2.601 | 88,011 | |
| $2.74 | -0.01 | -0.4% | $2.70 | $2.87 | $2.69 | 53,942 | |
| $2.75 | -0.18 | -6.1% | $2.958 | $2.958 | $2.66 | 66,024 | |
| $2.93 | -0.40 | -12.0% | $3.10 | $3.21 | $2.65 | 112,300 | |
| $3.33 | +0.22 | +7.1% | $2.94 | $3.443 | $2.93 | 182,700 | |
| $3.11 | +0.15 | +5.1% | $3.00 | $3.14 | $2.88 | 495,400 | |
| $2.96 | +0.31 | +11.7% | $2.65 | $3.34 | $2.65 | 586,700 | |
| $2.65 | -0.35 | -11.7% | $3.06 | $3.11 | $2.58 | 89,600 | |
| $3.00 | -0.34 | -10.2% | $3.40 | $3.44 | $2.62 | 5,655 | |
| $3.34 | -0.96 | -22.3% | $3.34 | $3.80 | $3.16 | 7,796 | |
| $4.30 | -0.10 | -2.3% | $4.56 | $4.60 | $4.30 | 904 | |
| $4.40 | -0.44 | -9.1% | $4.68 | $4.88 | $4.28 | 1,683 | |
| $4.84 | +0.40 | +9.0% | $4.48 | $5.04 | $4.34 | 3,175 | |
| $4.44 | -0.16 | -3.5% | $4.42 | $4.58 | $4.10 | 2,246 | |
| $4.60 | -0.26 | -5.3% | $4.58 | $4.60 | $3.72 | 3,916 | |
| $4.86 | +0.14 | +3.0% | $4.70 | $4.96 | $4.24 | 4,346 | |
| $4.72 | -1.32 | -21.9% | $5.78 | $5.98 | $4.60 | 12,127 | |
| $6.04 | -0.72 | -10.7% | $6.18 | $6.60 | $5.62 | 6,177 | |
| $6.76 | -1.84 | -21.4% | $8.02 | $8.04 | $6.62 | 17,385 | |
| $8.60 | -5.40 | -38.6% | $9.42 | $9.42 | $7.60 | 296,166 | |
| $14.00 | +6.04 | +75.9% | $8.20 | $31.20 | $8.00 | 444,899 | |
| $7.96 | -0.44 | -5.2% | $8.64 | $8.68 | $7.12 | 11,312 | |
| $8.40 | -4.94 | -37.0% | $9.70 | $10.00 | $8.24 | 5,326 | |
| $13.34 | -0.42 | -3.1% | $14.20 | $14.98 | $13.34 | 374 | |
| $13.76 | -1.70 | -11.0% | $15.60 | $15.60 | $13.44 | 330 | |
| $15.46 | -0.28 | -1.8% | $16.10 | $16.68 | $15.46 | 118 | |
| $15.74 | -0.62 | -3.8% | $16.20 | $16.24 | $15.56 | 95 | |
| $16.36 | -0.50 | -3.0% | $16.84 | $17.00 | $16.34 | 94 | |
| $16.86 | +0.86 | +5.4% | $16.76 | $17.20 | $16.02 | 329 | |
| $16.00 | -1.52 | -8.7% | $17.36 | $17.60 | $15.56 | 476 | |
| $17.52 | -0.60 | -3.3% | $18.00 | $18.56 | $17.40 | 237 | |
| $18.12 | -0.06 | -0.3% | $18.54 | $19.20 | $17.20 | 1,000 | |
| $18.18 | +0.18 | +1.0% | $17.80 | $19.40 | $17.20 | 548 | |
| $18.00 | +1.18 | +7.0% | $16.40 | $18.00 | $16.40 | 394 | |
| $16.82 | -3.78 | -18.3% | $20.20 | $20.20 | $16.82 | 889 | |
| $20.60 | 0.00 | 0.0% | $20.44 | $21.16 | $20.30 | 312 | |
| $20.60 | -0.80 | -3.7% | $21.36 | $21.36 | $20.50 | 215 | |
| $21.40 | +0.20 | +0.9% | $21.00 | $21.60 | $21.00 | 157 | |
| $21.20 | -0.40 | -1.9% | $22.00 | $22.30 | $21.00 | 242 | |
| $21.60 | -0.80 | -3.6% | $22.80 | $22.80 | $21.60 | 360 | |
| $22.40 | -0.60 | -2.6% | $22.80 | $23.00 | $22.20 | 218 | |
| $23.00 | +0.20 | +0.9% | $23.60 | $24.70 | $22.70 | 720 | |
| $22.80 | +0.60 | +2.7% | $22.80 | $22.80 | $22.20 | 203 | |
| $22.20 | -1.20 | -5.1% | $23.36 | $23.40 | $22.20 | 317 | |
| $23.40 | +0.80 | +3.5% | $22.80 | $23.80 | $22.40 | 323 | |
| $22.60 | +0.20 | +0.9% | $22.40 | $23.00 | $22.20 | 256 | |
| $22.40 | -0.60 | -2.6% | $22.80 | $24.60 | $22.10 | 907 | |
| $23.00 | -2.40 | -9.4% | $25.60 | $25.60 | $22.80 | 1,115 | |
| $25.40 | +0.60 | +2.4% | $25.00 | $26.00 | $23.60 | 2,548 | |
| $24.80 | +2.00 | +8.8% | $26.00 | $26.20 | $20.20 | 23,406 | |
| $22.80 | -0.40 | -1.7% | $23.00 | $23.32 | $22.42 | 131 | |
| $23.20 | 0.00 | 0.0% | $23.40 | $23.40 | $22.40 | 210 | |
| $23.20 | 0.00 | 0.0% | $23.00 | $23.40 | $22.80 | 247 | |
| $23.20 | -0.20 | -0.9% | $23.20 | $23.20 | $22.10 | 342 |
Splits
4 splits since 2024 · NASDAQ:SBFM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- NASDAQ:SBFM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 22, 2026
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Latest news
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Oct 22, 2026
Closed $3.34 (-22.3%) on Oct 22, 2026
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
Oct 9, 2026
Closed $6.76 (-21.4%) on Oct 9, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Oct 8, 2026
Closed $8.60 (-38.6%) on Oct 8, 2026
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Sep 24, 2026
Closed $16.00 (-8.7%) on Sep 24, 2026
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Sep 16, 2026
Closed $20.60 (0.0%) on Sep 16, 2026
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
Aug 31, 2026
Closed $22.40 (-2.6%) on Aug 31, 2026
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
Aug 26, 2026
Closed $24.80 (+8.8%) on Aug 26, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
Aug 19, 2026
Closed $23.40 (+4.5%) on Aug 19, 2026
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
Aug 7, 2026
Closed $24.60 (-12.1%) on Aug 7, 2026
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
Aug 4, 2026
Closed $26.20 (+12.0%) on Aug 4, 2026
Sunshine Biopharma Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 20 in the last 12 months · 123 in all · newest Oct 22, 2026 · oldest 2019
- Decks
- 1 deck · latest Feb 8, 2022
Where Sunshine Biopharma Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SBFM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:SBFM | BOATS | United States | USD |
Valuation
EV/sales −0.3× against a median of 2.3×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$12.15M USD
- P/E
- Loss
- EV/sales
- −0.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- 30.4%
- Operating margin
- −17.2%
- Net margin
- −17.4%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.95
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sunshine Biopharma Inc. · NASDAQ:SBFM | US$1.84M | −US$12.15M | n/a | −0.3× | n/a | 0.1× | −17.4% | 0.0× | 0.95 |
| Mangalam Drugs & Organics Ltd. · NSE:MANGALAM | US$4.71M | US$4.71M | n/a | 0.2× | n/a | 0.4× | −16.5% | 0.0× | n/a |
| Vivimed Labs Limited · NSE:VIVIMEDLAB | US$4.49M | US$46.53M | n/a | 6.2× | n/a | n/a | −252.1% | n/a | n/a |
| Acrux Limited · ASX:ACR | US$4.05M | US$4.59M | n/a | 1.5× | n/a | 4.2× | −13.0% | 1.7× | n/a |
| Scilex Holding Company · NASDAQ:SCLX | US$3.98M | US$98.96M | n/a | 3.1× | n/a | n/a | n/a | n/a | 1.46 |
| Scienture Holdings, Inc. · NASDAQ:SCNX | US$3.74M | US$8.36M | n/a | 5.6× | n/a | 0.1× | n/a | 0.2× | 1.74 |
| Sanai Health Industry Group Company Limited · HKEX:1889 | US$2.42M | −US$44.61M | n/a | −3.5× | n/a | 0.1× | −25.7% | 0.0× | n/a |
| Lasa Supergenerics Ltd. · NSE:LASA | US$2.17M | US$2.17M | n/a | 3.2× | n/a | 0.4× | −260.4% | 0.0× | n/a |
| Ortin Global Ltd · NSE:ORTINGLOBE | US$1.09M | US$1.09M | n/a | 131× | n/a | 8.1× | n/a | 0.0× | n/a |
| Rafarma Pharmaceuticals, Inc. (wy) · OTC:RAFA | US$877,670 | US$839,670 | 2.5× | 0.1× | n/a | 0.1× | 3.8% | 0.0× | 0.68 |
| Evofem Biosciences, Inc. · OTC:EVFM | US$834,940 | US$517,940 | n/a | 0.0× | n/a | n/a | −71.7% | n/a | -0.14 |
| Median of the others | US$3.08M | US$3.38M | 2.5× | 2.3× | 0.4× | −25.7% | 0.0× | 1.07 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 1120.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -39.00 · 1 analyst
- Revenue, year to Dec 2026
- 36.75M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Steve Slilaty | Chief Executive Officer |
| Camille Sebaaly | Chief Financial Officer |
| Malek Chamoun | Chief Development Officer |
| Michel Roy | CHIEF COMMERCIAL OFFICER |
Board
| Director | Role |
|---|---|
| Steve Slilaty | Chief Executive Officer |
| Andrew Keller | director |
| Camille Sebaaly | Chief Financial Officer |
| David Natan | director |
| Rabi Kiderchah | director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −4.9% |
| Q2 2026 | Aug 13, 2026 · After close | −4.2% |
| Q1 2026 | May 13, 2026 · After close | −28.9% |
| Q4 2025 | Feb 25, 2026 | +5.1% |
| Q3 2025 | Nov 13, 2025 · After close | −2.4% |
| Q2 2025 | Aug 12, 2025 · After close | +5.6% |
| Q1 2025 | May 15, 2025 | +7.9% |
| Q3 2024 | Nov 5, 2024 · After close | −6.3% |
| Q2 2024 | Aug 16, 2024 · After close | +5.8% |
| Q1 2024 | May 20, 2024 · After close | −17.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · After close | +75.4% |
| Q3 2023 | Nov 13, 2023 · Before open | −12.1% |
| Q2 2023 | Aug 10, 2023 · After close | 0.0% |
| Q1 2023 | May 11, 2023 · Before open | +69.8% |
| Q3 2022 | Nov 7, 2022 | −8.2% |
| Q2 2022 | Aug 4, 2022 · After close | +11.4% |
| Q1 2022 | May 6, 2022 | −22.8% |
| Q4 2021 | Mar 21, 2022 | 0.0% |
| Quarter to Sep 30, 2021 | Nov 9, 2021 | |
| Quarter to Jun 30, 2021 | Aug 9, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2022) | Investor deck | 15 slides | Feb 8, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common Units (or Pre-Funded Units) Closed: US$6M raised · US$0.55 a unit · Warrants at US$0.66 for 60 months · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Oct 9, 2026 |
| Registered direct offering of shares of Common Stock and pre-funded warrants Closed: US$2.46M raised · US$2.07 a share · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Apr 3, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.3M | 34.9M | 24.1M | 4.35M | 228.4K | 71.4K | 21.1K | 0 | 0 | 0 |
| Cost of revenue | 24.1M | 24.2M | 15.8M | 2.65M | 117.8K | 25.8K | 11.1K | 0 | 0 | 60.7K |
| Gross profit | 12.3M | 10.7M | 8.34M | 1.70M | 110.6K | 45.6K | 10.1K | 0 | 0 | -60.7K |
| Research and development | 604.3K | 933.9K | 1.86M | 811.9K | 672.2K | 1.73K | 15.2K | 12.8K | 0 | 32.8K |
| Selling, general and administrative | 18.5M | 14.0M | 10.1M | 8.90M | 650.5K | 606.6K | 622.7K | 1.21M | 850.6K | 899.6K |
| Operating income | -6.23M | -5.81M | -4.79M | -27.0M | -2.44M | -576.9K | -641.6K | -1.16M | -857.2K | -993.1K |
| Depreciation and amortization | 332.1K | 223.5K | 149.1K | 25.2K | 12.7K | 14.1K | 13.8K | 49.4K | 6.63K | 60.7K |
| EBITDA | -5.89M | -5.59M | -4.64M | -27.0M | -2.43M | -562.8K | -627.9K | -1.11M | -850.6K | -932.4K |
| Interest expense | 0 | 8.77K | 137.3K | 39.4K | 328.8K | 168.1K | 115.9K | 143.5K | 104.8K | 34.7K |
| Income before tax | -5.95M | -5.37M | -4.11M | -26.5M | -12.4M | -2.78M | -1.08M | -2.14M | -1.04M | -3.50M |
| Income tax | 21.6K | -234.9K | 395.2K | 233.3K | 0 | 0 | 383.4K | -41.5K | 1.29K | 2.47M |
| Net income | -5.98M | -5.13M | -4.51M | -26.7M | -12.4M | -2.78M | -1.66M | -2.16M | -1.04M | -3.50M |
| Earnings per share, basic | -1.44 | -7.32 | -351.36 | -1.76 | -4.76 | -2.73 | -0.15 | -0.71 | -0.02 | -0.01 |
| Earnings per share, diluted | -7.32 | -351.36 | -1.76 | -4.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.12M | 9.69M | 16.3M | 21.8M | 2.05M | 989.9K | 40.5K | 110.5K | 107.5K | 57.5K |
| Short-term investments | 7.59K | 7.59K | 7.59K | |||||||
| Receivables | 3.46M | 3.87M | 2.55M | 1.91M | 7.80K | 1.92K | 430 | 0 | 0 | |
| Inventory | 13.5M | 11.3M | 5.73M | 3.29M | 105.7K | 23.8K | 15.9K | 0 | -9.67K | |
| Current assets | 26.9M | 26.0M | 24.9M | 27.3M | 2.20M | 1.03M | 65.7K | 1.10M | 117.2K | 58.5K |
| Property, plant and equipment | 557.4K | 546.1K | 365.9K | 394.2K | 7.06K | 19.5K | 32.5K | 45.1K | 60.0K | 5.94K |
| Goodwill | 0 | 0 | 0 | 0 | 665.7K | 665.7K | 0 | |||
| Total assets | 30.1M | 30.6M | 27.3M | 29.2M | 2.20M | 1.05M | 98.1K | 1.15M | 257.5K | 64.4K |
| Accounts payable | 5.66M | 5.54M | 2.59M | 2.80M | 42.9K | 62.9K | 96.9K | 115.8K | 19.3K | 28.1K |
| Current liabilities | 6.44M | 6.31M | 5.55M | 6.93M | 91.2K | 1.05M | 833.5K | 912.5K | 751.1K | 274.1K |
| Long-term debt | 1.90M | 949.0K | 289.8K | 79.7K | ||||||
| Total debt | 812.4K | 952.5K | 657.7K | 765.3K | 1.90M | 949.0K | 715.6K | 952.6K | 802.3K | 237.0K |
| Total liabilities | 7.04M | 7.06M | 6.14M | 7.62M | 1.99M | 2.00M | 833.5K | 1.20M | 830.8K | 274.1K |
| Shareholders' equity | 23.0M | 23.5M | 21.2M | 21.6M | 211.7K | -954.8K | -735.4K | -55.8K | -573.4K | -209.7K |
| Shares outstanding | 24.5K | 2.58M | 14.0K | 22.6M | 2.59M | 1.73M | 35.3M | 4.28M | 45.9M | 769.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.33M | -12.5M | -8.78M | -5.25M | -1.83M | -657.3K | -495.8K | -512.8K | -543.5K | -314.2K |
| Capital spending | -174.5K | -1.66M | -82.3K | -194.0K | 0 | -1.19K | -860 | -18.9K | -3.72K | -3.44K |
| Free cash flow | -5.51M | -14.2M | -8.86M | -5.44M | -1.83M | -658.5K | -496.7K | -531.7K | -547.2K | -317.6K |
| Cash from investing | -836.3K | -1.98M | -656.1K | -14.6M | 0 | -1.19K | -15.3K | -13.9K | -84.0K | -3.44K |
| Cash from financing | 4.75M | 8.94M | 3.43M | 39.5M | 2.90M | 1.61M | 442.3K | 527.6K | 670.7K | 324.6K |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | 0 | -3.14M | -541.1K | -99.0K | 0 | 63.9K | 104.1K | |||
| Change in cash | -1.42M | -5.56M | -6.01M | 19.6M | 1.08M | 949.8K | -68.8K | 926 | 43.2K | 7.00K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-1 · Registration statement | Nov 18, 2026 | Offer document | SEC |
| DEFA14A · Additional proxy material | Nov 13, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 12, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| DEF 14C | Oct 27, 2026 | Meeting notice | SEC |
| PRE 14C | Oct 14, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 14, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 9, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Oct 9, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 8, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 5, 2026 | Big-stake notice | SEC |
| S-1 · Registration statement | Oct 2, 2026 | Offer document | SEC |
| DEF 14C | Sep 28, 2026 | Meeting notice | SEC |
| DRS · Draft registration statement | Sep 24, 2026 | Offer document | SEC |
| PRE 14C | Sep 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Sep 16, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 8, 2026 | Offer document | SEC |
| S-1 · Registration statement | Aug 28, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 28, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 20, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 10, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2026 | Big-stake notice | SEC |
| DEF 14C | Jun 8, 2026 | Meeting notice | SEC |
| PRE 14C | May 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 29, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | May 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 19, 2026 | Material contract | SEC |
| 424B4 · Prospectus | May 19, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 19, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 18, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 18, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 14, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 14, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| S-1 · Registration statement | May 12, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 4, 2026 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Apr 28, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Apr 28, 2026 | Offer document | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2026 | Results | SEC |
| 10-K · Annual report | Apr 3, 2026 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2026 | Explanation request | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| DEF 14C | Mar 2, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 20, 2026 | Meeting outcome | SEC |
| PRE 14C | Feb 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Management or board change | SEC |
| 8-K · Current report | Dec 12, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Oct 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| RW · Request to withdraw a registration | Aug 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 11, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 4, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Jul 25, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 19, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 11, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 3, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2025 | Results | SEC |
| 10-K · Annual report | Apr 1, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 21, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2025 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jan 13, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 424B4 · Prospectus | Nov 12, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| POS AM · Amendment to an effective registration | Nov 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Oct 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 20, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 19, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 16, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2024 | Explanation request | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| DEF 14C | Jul 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 2, 2024 | Meeting outcome | SEC |
| PRE 14C | Jul 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 1, 2024 | Current report | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 8-K · Current report | Jun 7, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 20, 2024 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | May 15, 2024 | Explanation request | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| DEF 14C | Mar 15, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 6, 2024 | Material contract | SEC |
| PRE 14C | Mar 5, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| DEF 14C | Mar 4, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 1, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 21, 2024 | Big-stake notice | SEC |
| PRE 14C | Feb 21, 2024 | Meeting notice | SEC |
| 8-K · Current report | Feb 16, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Feb 15, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 424B4 · Prospectus | Feb 14, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 9, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 9, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2024 | Other filings | SEC |
| S-1 · Registration statement | Feb 1, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 30, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jan 8, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 7, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2023 | Current report | SEC |
| 8-K · Current report | Oct 20, 2023 | Material contract | SEC |
| DEFA14A · Additional proxy material | Oct 19, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 18, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 13, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Sep 21, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 5, 2023 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Aug 29, 2023 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 25, 2023 | Meeting notice | SEC |
| 8-K · Current report | Aug 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Jun 6, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Jun 5, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 1, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 1, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 25, 2023 | Offer document | SEC |
| D | May 17, 2023 | Other filings | SEC |
| 8-K · Current report | May 16, 2023 | Material contract | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 2, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 19, 2023 | Current report | SEC |
| 10-K · Annual report | Apr 3, 2023 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2023 | Explanation request | SEC |
| 8-K · Current report | Mar 24, 2023 | Current report | SEC |
| 8-K · Current report | Feb 28, 2023 | Material contract | SEC |
| 8-K · Current report | Feb 13, 2023 | Current report | SEC |
| 8-K · Current report | Feb 10, 2023 | Material contract | SEC |
| 8-K/A · Current report, amended | Dec 12, 2022 | Current report | SEC |
| 8-K · Current report | Dec 9, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2022 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 2, 2022 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 26, 2022 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2022 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Aug 3, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 6, 2022 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 23, 2022 | Other filings | SEC |
| 424B3 · Prospectus | May 20, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 18, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 18, 2022 | Other filings | SEC |
| S-3 · Registration statement | May 10, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2022 | Quarterly report | SEC |
| D | Apr 29, 2022 | Other filings | SEC |
| 8-K · Current report | Apr 28, 2022 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2022 | Other filings | SEC |
| 8-K · Current report | Apr 8, 2022 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 8, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 7, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2022 | Other filings | SEC |
| S-3 · Registration statement | Mar 30, 2022 | Offer document | SEC |
| 8-K · Current report | Mar 24, 2022 | Current report | SEC |
This page holds 200 of 433 filings. Open Filings
Cap table
Built by 6ix from Sunshine Biopharma Inc.’s releases · as of Oct 9, 2026
- Common shares
- 823,772
- Fully diluted
- 823,772
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 823,772 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.66 · expire about Oct 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 823,772 |
| Oct 22, 2026 | |
| May 28, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Natan Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Board Member · Since at least Apr 22, 2026); Indaptus Therapeutics, Inc. (Director · Since at least Jan 7, 2026); Sow Good Inc. (Director · Since at least Dec 31, 2025); FiEE, Inc (Director · Since at least Nov 8, 2023); The Crypto Company (Chief Financial Officer · Mar 12, 2025 – Mar 12, 2025 · Past); Bio Green Med Solution, Inc. (Director · Jan 2, 2025 – Feb 26, 2025 · Past); CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); Vivakor, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past); NetBrands Corp. (Director · Feb 24, 2021 – Apr 25, 2022 · Past); PharmaNet Development Group Inc (Former EVP · Aug 3, 2007 – Dec 10, 2007 · Past) | director · Since at least Feb 10, 2022 |
| Andrew I Telsey | Director · Oct 31, 2021 – Oct 31, 2021 · Past |
| Andrew Keller | director · Since at least Nov 5, 2026 |
| Camille Sebaaly | Chief Financial Officer · Since at least Aug 7, 2026 |
| James Daniel Kish | Director · Oct 31, 2021 – Oct 31, 2021 · Past |
| Malek Chamoun | Chief Development Officer · Since at least Nov 5, 2026 |
| Michel Roy | CHIEF COMMERCIAL OFFICER · Since at least Jan 15, 2025 |
| Rabi Kiderchah | director · Since at least Nov 5, 2026 |
| Steve Slilaty | Chief Executive Officer · Since at least Sep 24, 2026 |
Log in to ask 6ix AI your own questions about Sunshine Biopharma Inc.